Contemporary Management of Overactive Bladder

References

• . Abrams P, Cardozo L, Fall M,; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standarisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178
   PubMed Web of Science ®Google Scholar
• . Cartwright R, Renganathan A, Cardozo L. Current management of overactive bladder. Curr Opin Obstet Gynecol. 2008;20(5):489–495
   PubMed Web of Science ®Google Scholar
• . Irwin DE, Milsom I, Hunskaar S,. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6): 1306–1314
   PubMed Web of Science ®Google Scholar
• . Stewart WF, Van Rooyen JB, Cundiff GW,. Prevalence and the burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336
   PubMed Web of Science ®Google Scholar
• . Abrams P, Kelleher C, Lerr L, Rogers R. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6( 11 suppl):S580–S590
   PubMed Web of Science ®Google Scholar
• . Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6( 11 suppl):574–579
   PubMed Web of Science ®Google Scholar
• . Chapple CR, Khullar V, Gabriel Z,. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562
   PubMed Web of Science ®Google Scholar
• . Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004;63( suppl 3A):32–41
   PubMed Web of Science ®Google Scholar
• . Nygaard I, Bryant C, Dowell C, Wilson PD; Cochrane Incontinence Group. Lifestyle interventions for the treatment of urinary incontinence in adults. Cochrane Database of Syst Rev. 2002;CD003505
   Google Scholar
• . Diokno AC, Sampselle CM, Herzog AR,. Prevention of urinary incontinence by behavioral modification program: a randomized, controlled trial among older women in the community. J Urol. 2004; 171(3): 1165–1171
   PubMed Web of Science ®Google Scholar
• . Lee RA, Balick MJ. Rx: Caffeine. Explore. 2006;2(1):55–59
   Google Scholar
• . Riesenhuber A, Boehm M, Posch M, Aufricht C. Diuretic potential of energy drinks. Amino Acids. 2006;31(1):81–83
   PubMed Web of Science ®Google Scholar
• . Creighton SM, Stanton SL. Caffeine: does it affect your bladder? Br J Urol. 1990;6(6):613–614
   Google Scholar
• . Lee JG, Wein AJ, Levin RM. The effect of caffeine on the contractile response of the rabbit urinary bladder to field stimulation. Gen Pharmacol. 1993;24(4):1007–1011
   PubMedGoogle Scholar
• . Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs. 2002; 11(8):560–565
   PubMedGoogle Scholar
• . Dallosso HM, McGrother CW, Matthews RJ, Donaldson MM. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int. 2003;92(1):69–77
   PubMed Web of Science ®Google Scholar
• . Dasgupta J, Elliott RA, Doshani A, Tincello DG. Enhancement of rat bladder contraction by artificial sweeteners via increased extracellular Ca2+ influx. Enhancement Toxicol Appl Pharmacol. 2006;217(2):216–224
   PubMed Web of Science ®Google Scholar
• . Smith JH, Berghmans B, Burgio K,. Adult conservative management. In: Abrams P, Cardozo L, Khoury S, eds. Incontinence. Paris, France: Health Publications Ltd., Editions 21; 2009:1025–1120
   Google Scholar
• . Fitzgerald MP, Stablein U, Brubaker L. Urinary habits among asymptomatic women. Am J Obstet Gynec. 2002;187(5):1384–1388
   PubMed Web of Science ®Google Scholar
• . Dowd TT, Bampbell JM, Jones JA. Fluid intake and urinary incontinence in older community-dwelling women. J Community Health Nursing. 1996;13(3):179–186
   PubMedGoogle Scholar
• . Panel on Dietary Reference Intakes for Electrolytes and Water. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. In: Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, ed. Food and Nutrition Board of the Institute of Medicine of the National Academies. Washington, DC: The National Academies Press; 2004:73–185
   Google Scholar
• . Newman DK. Self-care practices and lifestyle changes to reduce urinary symptoms. In: Newman DK, Wein AJ, eds. Managing and Treating Urinary Incontinence. Baltimore, MD: Health Professions Press; 2009:233–243
   Google Scholar
• . Wyman JF. Management of urinary incontinence in adult ambulatory care populations. Ann Rev Nurs Res. 2000;18:171–195
   PubMedGoogle Scholar
• . Newman DK. Lifestyle interventions. In: Bourcier AP, McGuire EJ, Abrams P, eds. Pelvic Floor Disorders. Philadelphia, PA: Elsevier Saunders; 2004:269–276
   Google Scholar
• . Richter HE, Creasman JM, Myers DL,; Program to Reduce Incontinence by Diet and Exercise (PRIDE) Research Group. Urodynamic characterization of obese women with urinary incontinence undergoing a weight loss program: the Program to Reduce Incontinence by Diet and Exercise (PRIDE) trial. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(12):1653–1658
   PubMed Web of Science ®Google Scholar
• . Bump RC, Sugerman HJ, Fantl JA, McClish DK. Obesity and lower urinary tract function in women: effect of surgically induced weight loss. Am J Obstet Gynecol. 1992;167(2):392–397
   PubMed Web of Science ®Google Scholar
• . Subak LL, Whitcomb E, Shen H, Saxton J, Vittinghoff E, Brown JS. Weight loss: a novel and effective treatment for urinary incontinence. J Urol. 2005;174(1):190–195
   PubMed Web of Science ®Google Scholar
• . Nuotio M, Jylha M, Koivisto AM, Tammela TL. Association of smoking with urgency in older people. Eur Urol. 2001;40(2):206–212
   PubMed Web of Science ®Google Scholar
• . Bump RC, McClish DK. Cigarette smoking and urinary incontinence in women. Am J Obstet Gynecol. 1992;167(5):1213–1218
   PubMed Web of Science ®Google Scholar
• . Koley B, Koley J, Saha JK. The effects of nicotine on spontaneous contractions of cat urinary bladder in situ. Br J Pharmacol. 1984;83(2):347–355
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Sexton CC, Irwin DE,. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395
   PubMed Web of Science ®Google Scholar
• . Kemp S. Improving the nutrition of patients using Entera Fibre Plus. Br J Nurs. 1999;8(15):1027–1031
   PubMedGoogle Scholar
• . Arnaud MJ. Mild dehydration: a risk factor of constipation? Eur J Clin Nutr. 2003;57( suppl 2):S88–S95
   PubMed Web of Science ®Google Scholar
• . Folden SL, Backer JH, Maynard F,. Practice guidelines for the management of costipation in adults. http://www.rehabnurse.org/pdf/BowelGuideforWEB.pdf. Accessed January 10, 2012
   Google Scholar
• . Alling Moler L, Lose G, Jorgensen T. Risk factors for lower urinary tract sympomts in women 40 to 60 years of age. Obstet Gynec. 2000;96(3):446–451
   PubMed Web of Science ®Google Scholar
• . Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M. Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology. 2001;47(2):72–76
   PubMed Web of Science ®Google Scholar
• . Panayi DC, Khullar V, Digesu GA, Spiteri M, Hendricken C, Fernando R. Rectal distension: the effect on bladder function. Neurourol Urodyn. 2011;30(3):344–347
   PubMed Web of Science ®Google Scholar
• . Godec CJ. ‘Timed voiding’—a useful tool in the treatment of urinary incontinence. Urology. 1984;23(1):97–100
   PubMed Web of Science ®Google Scholar
• . Colling J, Owen TR, McCreedy M, Newman DK. The effect of a continence program on frail community dwelling elderly persons. Urologic Nursing. 2003;23:117–122, 127–131
   PubMedGoogle Scholar
• . Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract. 2009;63(8):1177–1191
   PubMed Web of Science ®Google Scholar
• . Wyman JF, Fantl JA. Bladder training in ambulatory care management of urinary incontinence. Urol Nurs. 1991;11(3):11–17
   PubMedGoogle Scholar
• . Wilson PD, Berghamns B, Hagen S,. Adult conservative management. In: Abrams CL, Khoury S, Wein AJ, eds. Incontinence: Proceedings From the Third International Consultation on Incontinence. Plymouth, UK: Health Publications, Ltd; 2005:855–964
   Google Scholar
• . Fantl J, Newman DK, Colling J,; for the Urinary Incontinence in Adults Guideline Update Panel. Urinary incontinence in adults: acute and chronic managment. Clincial practice guideline no. 2: Update (AHCPR publication no. 96-0692). Agency for Health Care and Policy Research; 1996
   Google Scholar
• . Newman DK. Behavioral treatments: implementing toileting, bladder training, and pelvic floor muscle rehabilitation programs. In: Newman DK, Wein AJ, eds. Managing and Treating Urinary Incontinence. Baltimore, MD: Health Professions Press; 2009:233–243
   Google Scholar
• . Wyman JF. Behavioral interventions for the patient with overactive bladder. J Wound, Ostomy, and Continence Nursing. 2005;32:S11–S15
   Google Scholar
• . Fantl JA, Wyman JF, McClish DK,. efficacy of bladder training in old women with urinar incontinence. JAMA. 1991;265(5):609–613
   PubMed Web of Science ®Google Scholar
• . Burgio KL. Behavioral treatment options for urinary incontinence. Gastroenterology. 2004;126(1 suppl 1):S82–S89
   PubMed Web of Science ®Google Scholar
• . Yoshimura N, Chancellor MB. Physiology and pharmacology of the bladder and urethra. In: Wein AJ, Kavoussi LR, Novick AC, eds. Campbell's Urology. 9th ed. Philadelphia, PA: Elsevier Saunders; 2007:1922–1972
   Google Scholar
• . Kegel AH. Progressive resistance exercise in the functional restoration of the perineal muscles. Am J Obstet Gynec. 1948;56(2):238–248
   PubMed Web of Science ®Google Scholar
• . Shafik A, Shafik IA. Overactive bladder inhibition in response to pelvic floor muscle exercises. World J Urol. 2003;20(6):374–377
   PubMed Web of Science ®Google Scholar
• . Burgio KL, Goode PS, Locher JL,. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA. 2002;288(18):2293–2299
   PubMed Web of Science ®Google Scholar
• . Abrams P, Cardozo L, Khoury S, Wein AJ. Promotion, Education and Organization for Continence Care. Plymouth, UK: Health Publication; 2005
   Google Scholar
• . Hay–Smith J, Domoulin C. Pelvic floor muscle training versus no treatment, or incactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev. 2006;1:CD002114
   Google Scholar
• . Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 2004;3:46–53
   PubMed Web of Science ®Google Scholar
• . Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor—which is the main mechanism of action? Eur Urol. 2003;43(1):1–5
   PubMed Web of Science ®Google Scholar
• . De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn. 2006;25(2):156–161
   PubMed Web of Science ®Google Scholar
• . Iijima K, De Wachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol. 2007;52(3):842–847
   PubMed Web of Science ®Google Scholar
• . Witte LP, Mulder WM, de la Rosette JJ, Michel MC. Muscarinic receptor antagonists for overactive bladder treatment: does one ft all? Curr Opin Urol. 2009;19(1):13–19
   PubMed Web of Science ®Google Scholar
• . Andersson KE, Chapple CR, Cardozo L,. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, eds. Incontinence. 4th ed. Paris, France: Health Publication Ltd., Editions 21; 2009:631–699
   Google Scholar
• . Andersson KE. Potential benefits of muscarinic M3 receptor selectivity. Eur Urol 2002;1(4):23
   Web of Science ®Google Scholar
• . Chapple C, Van Kerrebroeck P, Tubaro A,. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007;52(4):1204–1212
   PubMed Web of Science ®Google Scholar
• . Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9(10):1787–1796
   PubMed Web of Science ®Google Scholar
• . Beermann B, Hellstrom K, Rosen A. On the metabolism of propantheline in man. Clin Pharmacol Ther. 1972;13(2):212–220
   PubMed Web of Science ®Google Scholar
• . Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU. 2007;100(5):987–1006
   PubMed Web of Science ®Google Scholar
• . Ikeda K, Kobayashi S, Suzuki M. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(2): 97–103
   PubMed Web of Science ®Google Scholar
• . Brynne N, Stahl MM, Hallén B,. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35:287–295
   PubMed Web of Science ®Google Scholar
• . van Kerrebroeck P, Kreder K, Jonas U,. Tolterodine once daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57(3):414–421
   PubMed Web of Science ®Google Scholar
• . Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998;55(6):813–820
   PubMed Web of Science ®Google Scholar
• . Todorova A, Vonderheid–Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41(6):636–644
   PubMed Web of Science ®Google Scholar
• . Kim Y, Yoshimura N, Masuda H, De Miguel F, Chancellor MB. Intravesical instillation of human urine after oral administration of trospium, tolterodine, and oxybutynin in a rat model of detrusor overactivity. BJU Int. 2006;97(2):400–403
   PubMed Web of Science ®Google Scholar
• . Ruffmann R. A review of flavoxate hydrochloride in the treatment of urge incontinence. J Intern Med Res. 1988;16(5):317–330
   PubMed Web of Science ®Google Scholar
• . Guarneri L, Robinston E, Testa R. A review of flavoxate: pharmacology and mechanism of action. Drugs Today. 1994;30:91
   Google Scholar
• . Oka M, Kimura Y, Itoh Y,. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996;727(1–2):91–98
   PubMed Web of Science ®Google Scholar
• . Kimura Y, Sasaki Y, Hamada K,. Mechanisms of suppression of the bladder activity by flavoxate. Int J Urol. 1996;3(3):218–227
   PubMedGoogle Scholar
• . Haruno A. Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations. Arzneimittelforschung. 1992;42(6):815–817
   PubMed Web of Science ®Google Scholar
• . Andersson KE, Wein AJ. Pharmacologic management of storage and emptying failure. In: Wein AJ, Kavoussi LR, Novick AC, eds. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: Saunders; 2007:2091–2123
   Google Scholar
• . Kay GG, Abou–Donia MB, Messer WS Jr,. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–2201
   PubMed Web of Science ®Google Scholar
• . Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit. 2000;6(2):314–318
   PubMedGoogle Scholar
• . Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. 2007;14(7):595–597
   Google Scholar
• . Fink AM, Aylward G W. Buscopan and glaucoma: a survey of current practice. Clin Radiol. 1995;50(3):160–164
   PubMed Web of Science ®Google Scholar
• . Haylen BT, de Ridder D, Freeman RM,; International Urogynecological Association; International Continence Society. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20
   PubMed Web of Science ®Google Scholar
• . Payne C, Brown J, Castro D,. Research. In: Abrams P, Cardozo L, Khoury S, eds. Incontinence. Paris, France: Health Publications Ltd., Editions 21; 2009:1713–1766
   Google Scholar
• . Weiss JP, Blaivas JG, Bliwise DL,. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108(1):6–21
   PubMed Web of Science ®Google Scholar
• . Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170 (2 pt 1):649–653
   PubMed Web of Science ®Google Scholar
• . Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147 ( suppl 2):S88–S119
   PubMed Web of Science ®Google Scholar
• . Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol. 2001;166(3):1142–1147
   PubMed Web of Science ®Google Scholar
• . Wein AJ, Levin RM, Barrett DM. Voiding function: relevant anatomy, physiology, and pharmacology. In: Duckett JW, Howards ST, Grayhack JT, eds. Adult and Pediatric Urology. St. Louis, MO: Mosby; 1991:933–999
   Google Scholar
• . Chapple CR, Yamaguchi O, Ridder A,. Clinical proof of concept study (Blossom) shows novel b3 andrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl. 2007;7(3):239. Abstract 674
   Web of Science ®Google Scholar
• . Fowler CJ, Swinn MJ, Goodwin RJ, Oliver S, Craggs M. Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated. J Urol. 2000;163:881–883
   PubMed Web of Science ®Google Scholar
• . Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(1):96.e1–e5
   Web of Science ®Google Scholar
• . Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord. 2009;47(6): 486–491
   PubMed Web of Science ®Google Scholar
• . Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665
   PubMed Web of Science ®Google Scholar
• . Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007;99(2):247–262
   PubMed Web of Science ®Google Scholar
• . Kalsi V, Gonzales G, Popat R.. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452–457
   PubMed Web of Science ®Google Scholar
• . Reitz A, Denys P, Fermanian C,. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol. 2007;52(6):1729–1735
   PubMed Web of Science ®Google Scholar
• . Brubaker L, Richter HE, Visco A,; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–222
   PubMed Web of Science ®Google Scholar
• . Schmid D, Sauermann P, Werner M,. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176(1):177–185
   PubMed Web of Science ®Google Scholar